The US FDA (Food and Drug Administration) announced on the 27th that it has approved the emergency use of the new coronavirus vaccine developed by pharmaceutical giant Johnson & Johnson.
It is expected that the pace of vaccination will accelerate because this vaccine requires only one vaccination.
The FDA announced on the 27th that it has approved the emergency use of a new type of coronavirus vaccine developed by pharmaceutical giant Johnson & Johnson that requires only one vaccination.
As a result of clinical trials in about 40,000 people around the world, this vaccine is 66.1% effective in preventing moderate to severe symptoms after 28 days after inoculation, and is effective only in severe symptoms. It is said to have shown 85.4%.
Early reports also showed similar efficacy in South Africa and Brazil, where mutant virus infections have been confirmed.
Regarding safety, the FDA also states that "no serious concerns have been raised."
In the United States, the vaccines of major pharmaceutical company Pfizer and pharmaceutical company Moderna have been approved for emergency use, and this is the third type of vaccine.
The Physer and Moderna vaccines require two doses, while the Johnson End Johnson vaccine requires only one dose and can be stored in a refrigerator temperature of 2 to 8 degrees Celsius for at least 3 months. Is expected to accelerate.